By Len Zehr Nuvo Research (TSX:NRI) plans to release, in the first quarter of 2015, the results of a confirmatory Phase 2 study for a potential blockbuster allergic rhinitis drug, WF10, which could be a game-changing...
By Len Zehr Ruthigen (NASDAQ:RTGN) expects to complete enrollment at the end of the year of the first 20 patients, representing the first arm of the Phase 1/2 clinical trial of RUT58-60, which is intended for use as an...
By Len Zehr Tandem Diabetes (NASDAQ:TNDM), which now markets the popular t:slim Insulin Pump for people with Type 1 diabetes and has two new pumps awaiting FDA clearance, has taken a unique consumer-focused approach to...
By Len Zehr Closely held rEVO Biologics is enrolling patients in a Phase 3 clinical trial of its ATryn recombinant human antithrombin for the treatment of early-onset preeclampsia, with top-line data expected in the...
By Len Zehr CytoTools AG (DE000A0KFRJ1/T5O) of Germany and its Indian marketing partner, Centaur Pharmaceuticals, expect to receive regulatory clearance in the current quarter in India for lead product, DermaPro, to...
By Len Zehr After years of fruitless search for new therapies to slow the deadly progression of Alzheimer’s disease (AD), researchers are having more success with experimental treatments for the neuropsychiatric...
By Len Zehr A mollusk living in the coastal waters off California from Monterey to the Baja Peninsula may hold the key to new therapies to treat cancer and autoimmune diseases. Stellar Biotechnologies (OTCQB:SBOTF; TSX...
By Len Zehr As a co-founder of BiondVax Pharmaceuticals (TASE:BNDX), Ron Babecoff has led the Israeli developer of a universal flu vaccine since its inception in 2003. Prior to BiondVax, Dr. Babecoff was with Omrix...
By Len Zehr Using an unique and innovative technology known as peripheral arterial tone (PAT), Itamar Medical (TASE:ITMR) is detecting the functioning and health of arteries through a finger sensor for the diagnosis of...
By Len Zehr BioTuesdays.com recently sat down with the management team at Pivotal Therapeutics (OTCQX:PVTTF; CSE:PVO) to discuss the company’s VASCAZEN product that addresses Omega-3 deficiency in cardiovascular disease...